Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANITSCHKOW: Evolocumab for arterial wall inflammation
NCT02729025Phase 3Completed
- Sponsor
- Amgen
- Start
- Apr 2016
- Primary completion
- Apr 2018
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 3 trial of evolocumab in hyperlipidemia, elevated lipoprotein(a) (Lp(a)), sponsored by Amgen. Started Apr 2016; status: completed.
02
Drugs
evolocumab
03
Conditions
hyperlipidemiaelevated lipoprotein(a) (Lp(a))
Beyond the preview
Go deeper on NCT02729025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02729025.